共 50 条
- [1] Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET StudyCANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1152 - 1170Kim, TaeyunJang, Tae WonChoi, Chang MinKim, Mi-HyunLee, Sung YongChang, Yoon SooLee, Kye YoungKim, Seung JoonYang, Sei HoonRyu, Jeong SeonLee, Jeong EunLee, Shin YupPark, Chan KwonLee, Sang HoonJang, Seung HunYoon, Seong HoonOh, Hyung-Joo
- [2] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR MutationsANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157Chen, Chi-HanChang, John Wen-ChengChang, Ching-FuHuang, Chen-YangYang, Cheng-TaKuo, Chih-Hsi ScottFang, Yueh-FuHsu, Ping-ChihWu, Chiao-En
- [3] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung CancerCANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30Aredo, Jacqueline, VWakelee, Heather A.Neal, Joel W.Padda, Sukhmani K.
- [4] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancerInvestigational New Drugs, 2020, 38 : 1906 - 1914Satoshi IgawaTaihei OnoMasashi KasajimaSeiichiro KusuharaSakiko OtaniTomoya FukuiMasanori YokobaMasaru KubotaMasato KatagiriHisashi MitsufujiJiichiro SasakiKatsuhiko Naoki
- [5] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancerINVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914Igawa, SatoshiOno, TaiheiKasajima, MasashiKusuhara, SeiichiroOtani, SakikoFukui, TomoyaYokoba, MasanoriKubota, MasaruKatagiri, MasatoMitsufuji, HisashiSasaki, JiichiroNaoki, Katsuhiko
- [6] Sequential afatinib and osimertinib in patients withEGFRmutation-positive non-small-cell lung cancer: final analysis of the GioTag studyFUTURE ONCOLOGY, 2020, 16 (34) : 2799 - 2808Hochmair, Maximilian J.Morabito, AlessandroHao, DesireeYang, Cheng-TaSoo, Ross A.Yang, James C-HGucalp, RasimHalmos, BalazsMarten, AngelaCufer, Tanja
- [7] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational studyFUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874Hochmair, Maximilian J.Morabito, AlessandroHao, DesireeYang, Cheng-TaSoo, Ross A.Yang, James C-HGucalp, RasimHalmos, BalazsWang, LaraGolembesky, AmandaMaerten, AngelaCufer, Tanja
- [8] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in KoreaTRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +Lee, Sung YongChoi, Chang-MinChang, Yoon SooLee, Kye YoungKim, Seung JoonYang, Sei HoonRyu, Jeong SeonLee, Jeong EunLee, Shin YupPark, Ji YoungKim, Young-ChulOh, In-JaeJung, Chi YoungLee, Sang HoonYoon, Seong HoonChoi, JuwhanJang, Tae Won
- [9] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-AnalysisPHARMACOLOGY, 2023, 108 (01) : 8 - 16Pan, JieCai, XiaopingCao, ZhuoPan, JiongweiZheng, Hao
- [10] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCERDRUGS OF TODAY, 2013, 49 (09) : 523 - 535Bowles, D. W.Weickhardt, A.Jimeno, A.